Advion Reaches OEM, Distribution Deal with CAMAG for TLC/MS Interface Product | GenomeWeb

NEW YORK (GenomeWeb News) – Advion said on Monday it has signed an exclusive original equipment manufacturing and distribution partnership deal with Swiss firm CAMAG for Advion's TLC/MS interface product.

The two companies plan to commercialize a combined system to Advion's Synthetic Organic Chemistry and Peptide Synthesis global market segments, Advion said, adding it has exclusive marketing and support rights in certain geographies, including North America and parts of Europe.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.